Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy Glacier Bancorp, Inc. (GBCI)?

Page 1 of 2

Should Glacier Bancorp, Inc. (NASDAQ:GBCI) investors track the following data?

At the moment, there are tons of indicators shareholders can use to track publicly traded companies. Two of the most underrated are hedge fund and insider trading sentiment. At Insider Monkey, our research analyses have shown that, historically, those who follow the top picks of the elite hedge fund managers can trounce the S&P 500 by a superb amount (see just how much).

Just as crucial, positive insider trading sentiment is another way to analyze the financial markets. Just as you’d expect, there are a variety of motivations for an executive to drop shares of his or her company, but just one, very clear reason why they would behave bullishly. Various academic studies have demonstrated the useful potential of this method if investors understand where to look (learn more here).

What’s more, we’re going to discuss the recent info for Glacier Bancorp, Inc. (NASDAQ:GBCI).

How are hedge funds trading Glacier Bancorp, Inc. (NASDAQ:GBCI)?

In preparation for the third quarter, a total of 12 of the hedge funds we track held long positions in this stock, a change of 9% from the first quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists a select group of notable hedge fund managers who were boosting their stakes substantially.

Glacier Bancorp, Inc. (NASDAQ:GBCI)Out of the hedge funds we follow, Fisher Asset Management, managed by Ken Fisher, holds the largest position in Glacier Bancorp, Inc. (NASDAQ:GBCI). Fisher Asset Management has a $51.8 million position in the stock, comprising 0.1% of its 13F portfolio. On Fisher Asset Management’s heels is David Dreman of Dreman Value Management, with a $8.7 million position; 0.3% of its 13F portfolio is allocated to the company. Some other peers that hold long positions include Jim Simons’s Renaissance Technologies, Chuck Royce’s Royce & Associates and Neil Chriss’s Hutchin Hill Capital.

As one would understandably expect, particular hedge funds have jumped into Glacier Bancorp, Inc. (NASDAQ:GBCI) headfirst. Fisher Asset Management, managed by Ken Fisher, assembled the biggest position in Glacier Bancorp, Inc. (NASDAQ:GBCI). Fisher Asset Management had 51.8 million invested in the company at the end of the quarter. David Dreman’s Dreman Value Management also made a $8.7 million investment in the stock during the quarter. The following funds were also among the new GBCI investors: Jim Simons’s Renaissance Technologies, Chuck Royce’s Royce & Associates, and Neil Chriss’s Hutchin Hill Capital.

What do corporate executives and insiders think about Glacier Bancorp, Inc. (NASDAQ:GBCI)?

Legal insider trading, particularly when it’s bullish, is most useful when the company we’re looking at has seen transactions within the past half-year. Over the latest 180-day time period, Glacier Bancorp, Inc. (NASDAQ:GBCI) has experienced zero unique insiders purchasing, and zero insider sales (see the details of insider trades here).

We’ll check out the relationship between both of these indicators in other stocks similar to Glacier Bancorp, Inc. (NASDAQ:GBCI). These stocks are Cathay General Bancorp (NASDAQ:CATY), CVB Financial Corp. (NASDAQ:CVBF), Western Alliance Bancorporation (NYSE:WAL), WestAmerica Bancorp. (NASDAQ:WABC), and Umpqua Holdings Corp (NASDAQ:UMPQ). This group of stocks are the members of the regional – pacific banks industry and their market caps resemble GBCI’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!